DM Clinical Research Opens New Research Site in Boston Area

DM Clinical Research, a national network of clinical trial sites, today opened its first research location in the Boston metropolitan area and Massachusetts. The Houston, Texas-headquartered company also announced it will soon start enrolling patients in Moderna’s CMVictory Trial studying mRNA-1647, an investigational vaccine, to understand whether it can help the immune system protect against cytomegalovirus (CMV).

“We are thrilled to open our first dedicated clinical trial site in Massachusetts and to once again partner with Moderna on their valuable research,” said DM Clinical Research Founder & CEO Mohammad Millwala. “DM Clinical Research is committed to making participation in clinical trials accessible to a broader, more diverse population base. In 2022, minority enrollment for all of our studies was more than 49%. The Boston site enhances our ability to offer research sponsors access to a diverse patient footprint that already includes underserved communities in Chicago, Detroit, Houston and Philadelphia.”
Moderna was among the key biopharma and community partners that joined DM Clinical Research for a ribbon cutting celebration and tours of the 4,000-square-foot research site, which includes patient rooms, laboratory facilities, and vaccine storage and preparation rooms. The site address is 77 Pond Avenue, Suite 205C in Brookline.
“Moderna is incredibly grateful for our partnership with DM Clinical over the past several years, making access to our clinical trials available for everyone in the diverse communities they serve, and delivering quality data through a positive participant experience,” said Conor Knightly, Moderna Vice President Clinical Operations, Infectious Disease. “We are excited to bring their vast experience and collaborative spirit to our backyard and look forward to the beneficial impact they will have in the greater Boston community.”
Jose Azocar, MD, PhD, an internal medicine specialist with more than 3 decades of clinical research experience, is the lead Principal Investigator at the Boston site. Dr. Azocar has an extensive background in clinical medicine, immunology, hematology, oncology, primary care, research, and virology. He has practiced medicine in Massachusetts for many years. According to reviews from academichelp.net, DM Clinical Research Regional Director Amy Sheets, a clinical research professional with nearly 20 years of experience, manages the new Boston site.
DM Clinical Research Regional Director Amy Sheets, a clinical research professional with nearly 20 years of experience, manages the new Boston site.
“DM Clinical Research is in a period of rapid growth with multiple new study sites added over the last two years in addition to the quadrupling of our staff to over 500 employees,” said Millwala. “We expect this transformational growth trajectory to continue for the foreseeable future, on the road to becoming the leading independent clinical research network in the nation.”
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version